Overexpression of PPARG decreases susceptibility to VEN/DEC treatment. (A) Experimental protocol for generating VEN/DEC-resistant HL60 and MV4;11 cells OE PPARG and subsequent drug treatment (left). Western blot analysis of PPARγ protein expression in control vector vs PPARG-OE cell lines (right). (B) HL60 and MV4;11 cells transfected with either the control vector or PPARG-OE were treated with the indicated doses of VEN ± DEC for 72 hours after mCherry or GFP sorting, respectively. The number of viable cells (expressed as a percentage of untreated cells) was determined using the trypan blue exclusion method. (C) Apoptosis of treated cells was analyzed by flow cytometry. Cells transfected with the control vector were stained with mCherry/annexin V–APC, and PPARG-OE cells were stained with GFP/annexin V–APC. Representative flow cytometry plots showing GFP or mCherry (x-axis) and APC–annexin V staining (y-axis) are displayed on the left. The percentages of annexin V–positive cells are presented on the right. Data are expressed as the mean ± SD of 3 independent experiments. Differences between the groups were tested using the 2-tailed Student t test. ∗P < .05. APC, allophycocyanin; CMV, cytomegalovirus; GFP, green fluorescent protein.